Letters, Statements and Analysis - 2012

Communicating the importance of managed care pharmacy is a key part of AMCP’s work.   Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve. 

 Archives

2/22/2012

» HHS response to AMCP's comment letter on essential health benefits associated with the affordable insurance Exchanges

2/22/2012

» HHS response to AMCP's comment letter on coverage of preventive services under the Affordable Care Act (ACA)

2/13/2012

» AMCP comments to the FDA on New Drug; Revision of Postmarketing Reporting Requirements - Discontinuance  

2/7/2012

» AMCP summary of the CMS Proposed Rule on Medicaid Program Covered Outpatient Drugs  

2/3/2012

» AMCP comments to the Patient-Centered Primary Care Collaborative (PCPCC) on the proposed medication management guidelines 

1/31/2012

» AMCP comments to CMS on proposed changes to the Part D Reporting Requirements for Contract Year 2013 

1/31/2012

» AMCP comments to HHS on the Essential Health Benefits Bulletin issued by the Center for Consumer Information and Insurance Oversight (CCIIO) on December 16, 2011.  

1/20/2012

» AMCP comments to NQF on Patient Outcomes: All Cause Readmissions Expedited Review 2011: A Consensus Report  

1/19/2012

» AMCP comments on NQF Measure Application Partnership (MAP) Pre-Rulemaking Report   

1/13/2012

» AMCP comments to the Centers for Medicare & Medicaid Services (CMS) on enhancements to the Part C and Part D plan ratings 

1/5/2012

» The Department of Labor responds to AMCP on coverage of preventive services under the Affordable Care Act (ACA) 

1/4/2012
» AMCP comments to the Food and Drug Administration (FDA) on the proposed recommendations for enactment of the Generic Drug User Fee Act (GDUFA)